North Star Asset Management Inc. Acquires Shares of 71,575 Edwards Lifesciences Corporation $EW

North Star Asset Management Inc. bought a new stake in shares of Edwards Lifesciences Corporation (NYSE:EW) in the 2nd quarter, Holdings Channel reports. The fund bought 71,575 shares of the medical research company’s stock, valued at approximately $6,475,000.

A number of other hedge funds and other institutional investors have also modified their holdings of EW. BlackRock Inc. acquired a new stake in Edwards Lifesciences in the second quarter valued at $5,318,092,000. Bank of New York Mellon Corp bought a new position in Edwards Lifesciences in the second quarter worth about $1,274,082,000. Norges Bank bought a new stake in shares of Edwards Lifesciences in the 4th quarter worth approximately $803,686,000. Bank of America Corp DE bought a new stake in Edwards Lifesciences in the second quarter valued at $605,397,000. Finally, Deutsche Bank AG acquired a new position in Edwards Lifesciences during the 2nd quarter valued at about $516,552,000. 79.46% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 619 shares of the stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $92.03, for a total transaction of $56,966.57. Following the transaction, the vice president owned 40,034 shares in the company, valued at $3,684,329.02. This trade represents a 1.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 1,857 shares of company stock worth $170,305 in the last 90 days. Company insiders own 0.31% of the company’s stock.

Edwards Lifesciences Stock Down 0.9%

EW stock opened at $89.97 on Friday. Edwards Lifesciences Corporation has a 12-month low of $72.30 and a 12-month high of $96.29. The company has a quick ratio of 3.77, a current ratio of 4.52 and a debt-to-equity ratio of 0.06. The company has a market cap of $51.81 billion, a price-to-earnings ratio of 51.71, a PEG ratio of 2.38 and a beta of 0.85. The company has a 50 day moving average of $89.48 and a two-hundred day moving average of $84.99.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.74 by $0.04. The business had revenue of $1.74 billion during the quarter, compared to analyst estimates of $1.70 billion. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The firm’s revenue was up 13.6% on a year-over-year basis. During the same period in the previous year, the company earned $0.67 EPS. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. On average, equities analysts anticipate that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on EW shares. Citigroup lifted their price target on Edwards Lifesciences from $101.00 to $110.00 and gave the company a “buy” rating in a report on Wednesday, July 8th. JPMorgan Chase & Co. increased their price target on Edwards Lifesciences from $100.00 to $105.00 and gave the company an “overweight” rating in a research note on Friday, July 24th. UBS Group assumed coverage on shares of Edwards Lifesciences in a research report on Tuesday, July 28th. They set a “buy” rating and a $110.00 price objective for the company. Royal Bank Of Canada lifted their target price on Edwards Lifesciences from $100.00 to $110.00 and gave the stock an “outperform” rating in a report on Monday, July 13th. Finally, TD Cowen reiterated a “buy” rating on shares of Edwards Lifesciences in a report on Tuesday, July 21st. Seventeen research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $100.27.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.